Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2006; 12(33): 5293-5300
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5293
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5293
Table 1 Baseline characteristics of patients (Information are not available for all patients) n (%)
Characteristic | All(n = 188) | PegIFN +RBV + AMA(n = 106) | IFN+RBV+AMA(n = 82) |
Male/Female | 146/42 | 79/27 | 67/15 |
Age | |||
≤ 40 yr | 42 (22) | 23 (22) | 19 (23) |
> 40 yr | 146 (78) | 83 (78) | 63 (77) |
BMI | |||
≤ 25 kg/m2 | 107 (64) | 60 (65) | 47 (63) |
> 25 kg/m2 | 61 (36) | 33 (35) | 28 (37) |
ALT | |||
≤ 120 UI/L | 107 (62) | 64 (65) | 43 (58) |
> 120 UI/L | 66 (38) | 35 (35) | 31 (42) |
HCV genotype | |||
1 | 147 (78) | 82 (77) | 65 (79) |
2 | 21 (11) | 12 (11) | 9 (11) |
3 | 8 (4) | 7 (7) | 1 (1) |
4 | 12 (6) | 5 (5) | 7 (9) |
HCV RNA | |||
≤ 2 x 106 copies/mL | 74 (73) | 41 (76) | 33 (69) |
> 2 x 106 copies/mL | 28 (27) | 13 (24) | 15 (31) |
Stage | |||
≤ 3 | 127 (69) | 71 (70) | 56 (68) |
> 3 | 56 (31) | 30 (30) | 26 (32) |
Grade | |||
≤ 10 | 167 (92) | 94 (91) | 73 (92) |
> 10 | 15 (8) | 9 (9) | 6 (8) |
Table 2 Sustained virologic response for all treatment groups combined according to the baseline characteristics of patients
Characteristics | Sustained virologic response | P1 | |
Genotype 1 | 32/147 | 22% | 0.0085 |
Non 1 | 18/41 | 44% | |
Age ≤ 40 yr | 13/42 | 31% | NS |
> 40 yr | 37/146 | 25% | |
BMI ≤ 25 kg/m2 | 32/107 | 30% | NS |
> 25 kg/m2 | 12/61 | 20% | |
Stage ≤ 3 | 37/127 | 29% | NS |
> 3 | 12/56 | 21% | |
Grade ≤ 10 | 42/167 | 25% | 0.03 |
> 10 | 8/15 | 53% | |
ALT ≤ 120 UI/L | 22/107 | 21% | 0.03 |
> 120 UI/L | 24/66 | 36% | |
HCV-RNA ≤ 2 × 106 copies/mL | 23/74 | 31% | NS |
> 2 × 106 copies/mL | 7/28 | 25% | |
Previous Total IFN ≤ 500 MU | 20/91 | 22% | NS |
> 500 MU | 25/82 | 30% |
Table 3 Sustained virologic response in patients treated with Peg IFN or standard IFN according to the baseline characteristics of patients
Characteristic | PegIFN+RBV+AMA | IFN+RBV+AMA | P | ||
Genotype 1 | 21/82 | 26% | 11/65 | 17% | NS |
Non 1 | 13/24 | 54% | 5/17 | 29% | NS |
Age ≤ 40 yr | 11/23 | 48% | 2/19 | 11% | 0.017 |
> 40 yr | 23/83 | 28% | 14/63 | 22% | NS |
BMI ≤ 25 kg/m2 | 22/60 | 37% | 10/47 | 21% | NS |
> 25 kg/m2 | 8/33 | 24% | 4/28 | 14% | NS |
Stage ≤ 3 | 27/71 | 38% | 10/56 | 18% | 0.018 |
> 3 | 6/30 | 20% | 6/26 | 23% | NS |
Grade ≤ 10 | 28/94 | 30% | 14/73 | 19% | NS |
> 10 | 6/9 | 67% | 2/6 | 33% | NS |
ALT ≤ 120 UI/L | 17/64 | 27% | 5/43 | 12% | NS |
> 120 UI/L | 15/35 | 43% | 9/31 | 29% | NS |
HCV-RNA ≤ 2 × 106 copies/mL | 15/41 | 37% | 8/33 | 24% | NS |
> 2 × 106 copies/mL | 6/13 | 46% | 1/15 | 7% | 0.029 |
Table 4 Reasons for treatment discontinuation
PegIFN +RBV+ AMA(n = 106) | IFN+RBV+AMA(n = 82) | |
Treatment discontinuation for any | 10 (9.4%) | 17 (20.7%) |
Reason1 | ||
Study drug noncompliance | 2 | 11 |
Demyelinizing neuropathy | 1 | |
Depression | 1 | 1 |
Erythema | 1 | |
Pulmonary fibrosis | 1 | |
Hyperthyroidism | 1 | |
Hyperthyroidism & Insomnia | 1 | |
Increased ALT | 1 | |
Leukopenia | 1 | 3 |
Dyspnoea, Cough, Pruritus | 1 | |
Unknown reason | 1 |
- Citation: Fargion S, Borzio M, Maraschi A, Cargnel A, Lombardo TPOTGE. Triple antiviral therapy in HCV positive patients who failed prior combination therapy. World J Gastroenterol 2006; 12(33): 5293-5300
- URL: https://www.wjgnet.com/1007-9327/full/v12/i33/5293.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i33.5293